Goldman Sachs’s Serina Therapeutics SER Stock Holding History

Goldman Sachs’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-393	Closed	-$13K	–	5525
2020 Q1	$13K	Buy	+393	New	+$18.5K	﹤0.01%	5153

Other funds holding SER

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Goldman Sachs's SER Position: Q2 2020 in Review

Goldman Sachs sold out of Serina Therapeutics (SER) in Q2 2020, closing a stake of 393 shares — an estimated $13K sold.

Goldman Sachs first reported a position in SER in Q1 2020 and held it in 1 quarter. The position peaked at $13K in Q1 2020. 48 funds tracked by Wall St. Rank hold SER as of Q2 2020.

Goldman Sachs reported no remaining Serina Therapeutics position as of Q2 2020 after selling out during the quarter.
Goldman Sachs sold 393 Serina Therapeutics shares in Q2 2020, an estimated $13K.
Goldman Sachs first reported a position in Serina Therapeutics in Q1 2020 and held it in 1 quarter.
Goldman Sachs's Serina Therapeutics position peaked at $13K in Q1 2020.
48 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2020.

Based on Goldman Sachs's 13F filing for Q2 2020, filed 12 Aug 2020.